+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.

Age: 18Years +All GendersPhase 3
330 locations
R

Actively Recruiting

Researchers are evaluating mocertatug rezetecan Mo-Rez in treating endometrial cancer EC compared to standard chemotherapy options. The study aims to understand how well Mo-Rez works and how safe and tolerable it is for participants, including comparing side effects between Mo-Rez and standard treatments. This is a phase 3 randomized, open-label study focusing on treatment after prior platinum-based chemotherapy and immunotherapy. Participants will receive either mocertatug rezetecan or standard of care chemotherapy, which includes paclitaxel or doxorubicin, based on the investigators choice. The study uses a parallel design to compare these treatments directly. Treatment and assessments will continue for up to about 97 weeks for primary outcomes, with longer follow-up for secondary outcomes up to approximately 156 weeks. Throughout the study, participants will undergo multiple evaluations, including tumor response assessments by blinded independent central review and investigator assessments. Researchers will monitor progression-free survival, overall survival, treatment side effects, and quality of life using specialized questionnaires. Laboratory tests, vital signs, ECGs, and antibody measurements against the study drug will also be performed. The total participation time may extend over several years to capture long-term outcomes and safety data.

Age: 18Years +FEMALEPhase 3
56 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of crizanlizumab, a biological drug given at 5 mgkg, compared to a placebo in adolescents and adults aged 12 years and older who have Sickle Cell Disease and experience frequent vaso-occlusive crises VOCs. This phase III, multicenter, randomized, double-blind study includes patients who may or may not be receiving hydroxyurea or hydroxycarbamide therapy. The study aims to better understand how crizanlizumab impacts the rate and severity of VOCs in this population. Participants will be randomly assigned in a 21 ratio to receive either crizanlizumab or placebo, with both groups continuing standard care. The treatment is given as an intravenous infusion and the study allows patients to continue stable doses of hydroxyurea or hydroxycarbamide if they are already on these therapies. The randomization is stratified by hydroxyureahydroxycarbamide use and geographic region. The study treatment period lasts for one year, during which participants receive regular infusions and monitoring. During the trial, participants will be closely monitored with healthcare assessments to track the number of healthcare professional-managed VOCs, time to first VOC, and other important measures such as duration of VOCs, antibody development to the study drug, and changes in hemoglobin levels. Safety is closely evaluated through recording of adverse events over a two-year period. Participants will have regular visits for treatment and evaluation throughout the study, which is expected to last up to six years including follow-up and completion phases.

Age: 12Years - 100YearsAll GendersPhase 3
36 locations
E

Actively Recruiting

Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.

Age: 18Years +All GendersPhase 3
671 locations
E

Actively Recruiting

Researchers are investigating the impact of socioeconomic deprivation on health outcomes after surgery in Brazil. This retrospective study focuses on patients aged 16 and older who had elective or urgent surgeries in public and private hospitals during 2024. The study aims to understand how social factors like income, education, and living conditions influence risks during and after surgery, addressing gaps in knowledge especially in low- and middle-income countries. The study does not involve any treatment or intervention. Instead, it analyzes existing hospital data, including patient demographics, clinical details, and surgical information. Socioeconomic deprivation is measured using area-level indices linked to patients residential addresses. Patients are grouped by deprivation levels, and the association between these groups and surgery outcomes is studied. Participants health records will be reviewed for outcomes such as 30-day in-hospital postoperative mortality and postoperative care details like intensive care admission. The study collects data anonymously, focusing on factors like age, sex, surgical urgency, and hospital type. Results will help identify vulnerable patients and improve risk prediction models considering social factors, aiming to reduce health inequities in surgical care.

Age: 16Years +All Genders
7 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of acalabrutinib combined with rituximab in elderly andor frail patients with diffuse large B-cell lymphoma DLBCL who have not received prior treatment and are not suitable for standard chemotherapy. This phase II, open-label, single-arm study focuses on patients aged 65 and older, targeting those who are either over 80 or between 65 and 79 but ineligible for standard chemoimmunotherapy. Participants will receive oral acalabrutinib starting on Cycle 1 Day 1 for up to 28 cycles or until disease progression or other criteria lead to stopping treatment. Rituximab will be given intravenously on Cycle 1 Day 15 and by subcutaneous injection from Cycle 2 through Cycle 8. The treatment phase includes up to 8 cycles of rituximab and up to 28 cycles of acalabrutinib. The study lasts up to 108 weeks, including up to 28 days for screening and 104 weeks for treatment and follow-up. Researchers will monitor adverse events of Grade 3 to 4 severity, response rates, survival outcomes, and physical function using tests like the Timed Up and Go. Safety and efficacy will be assessed throughout treatment and up to 3.5 years after starting, with ongoing monitoring of disease status and patient health.

Age: 65Years - 99YearsAll GendersPhase 2
57 locations